Wednesday, October 23, 2013

Product Focus: LEXSY gene fusion vaccines

Jena Bioscience GmbH's LEXSY was used for the development of a live tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis, based on L. donovani A2 antigen and cysteine proteinases CPA and CPB (Saljoughian et al., 2013). It was found that immunizations with this vaccine protected BALB/c mice against L. infantum challenge and were associated with a Th1-type immune response.
Cervical cancer is the third most prevalent cause of cancer in women worldwide and associated with human papilloma viruses (HPV). Recombinant LEXSY expressing gene fusions of HPV16 E7 antigen with GFP (Salehi et al., 2012) or chaperone gp96 regions (Hosseinzadeh et al., 2013) were found to significantly induce the levels of IgG2a and IFN╬│ in a C57BL/6 mice model. Furthermore, live L. tarentolae-E7-CT(gp96) vaccine indicated significant protective effects as compared to control groups.

 LEXSY products – all you need for cloning, expression strain selection, and cultivation

LEXSY Expression Kits
Convenient all-in-one expression kits allowing constitutive or inducible, intracellular or secretory expression of target proteins
LEXSY Strains & Cultivation Kits
The LEXSY expression hosts, as strains or complete ready-to-grow cultivation kits.
LEXSY Cultivation Media
Complex and synthetic media for optimal growth of LEXSY strains
LEXSY Antibiotics
For efficient selection of recombinant strains
LEXSY Molecular Tools
Expression vectors and useful primers
PCR and Cloning enzymes
All restriction enzymes for the pLEXSY cloning sites, ligases, polymerases etc.

References

Post a Comment